On June 11, Innovent Biologics fell 3.03% in regular trading, trading at 72.2 HKD/share, with trading volume of HKD 256 million. The decline reflects continued market concerns over regulatory approval of the company's landmark deal with Pfizer, compounded by broad-based selling across the biotech sector.

Innovent Biologics previously announced a USD 10.5 billion global strategic partnership with Pfizer on May 29, which initially drove the stock up over 11%. Under the agreement, Innovent will receive USD 650 million upfront and is eligible for up to USD 9.85 billion in development, regulatory, and commercialization milestone payments, while retaining rights in Greater China. However, since the initial surge, the stock has retreated over multiple consecutive trading sessions as the market questions whether the transaction can secure timely regulatory clearance.

Within the Biotechnology sector, systematic selling pressure persisted. Among individual stocks, BeiGene down 5.28%, SKB Bio down 4.78%, Akeso down 4.21%, 3SBio down 3.70%, and Zai Lab down 1.28%, forming broad sector weakness that weighed on Innovent Biologics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)